ClinicalTrials.gg
RecruitingNCT07547228Updated Apr 29, 2026

A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

A Phase 1/2 interventional study of PRL3-ZUMAB and Normal Saline (0.9% Sodium Chloride) in Neovascular Age Related Macular Degeneration, sponsored by Intra-IMMUSG Pte Ltd. Recruiting at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Intra-IMMUSG Pte Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2025, registered Apr 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 24 studies in Macular Degeneration with a site in Singapore — 6 open to participants now, 10 under way, 2 of them phase 3. Macular Degeneration · Singapore.

Planned enrollment
18th of 18
15 · median 327
Started
2025
with 6 others
Phase 1/2
Only one
of the 24
Registered
23rd of 24
by date
Lead sponsor
1 of 24
Intra-IMMUSG Pte Ltd

Among the 24 studies in Macular Degeneration with a site in Singapore, this one is the 18th largest by planned enrollment of the 18 interventional ones that give a count, is one of 7 that started in 2025, is the only one in phase 1/2, and was the 23rd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

6 of the 24 studies in Macular Degeneration with a site in Singapore are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Macular Degeneration with a site in Singapore, or all of them as a file.
02

Study summary

Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD).

PRL3-zumab will be administered intravenously in 2-week interval for 3 doses. Normal saline (0.9% Sodium Chloride w/v) will be used in placebo treatment. The study will consist of 3 arms.

Arm-1: PRL3-zumab 3mg/kg intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-2: PRL3-zumab 6mg/kg intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-3: Placebo (normal saline 0.9% sodium chloride w/v) intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=3)

Initial 3 arms will be conducted on patients who failed Standard-of-Care (SOC) therapy. Response assessment will be done at every 4 weeks from last dose of treatment till 24-week.

Randomization:

Randomization will be done in 2:2:1 manner on PRL3-zumab (Arm 1), 3mg/kg (n=6); PRL3-zumab (Arm 2), 6mg/kg (n=6); and placebo group (Arm 3) (n=3). Randomization can be achieved using random number table which will be prepared before the commencement of clinical trial.

The allocation of participants will be done by Investigator and will be concealed from the participants.

Blinding:

Single blinding will be done for this trial in which all participants are unaware of their treatment assignment. No blinding will be done on Investigator.

Primary Endpoints:

  1. Safety:

    • Adverse Events: Frequency and severity of adverse events throughout the primary outcome assessment period will be assessed by the Investigator for severity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 or later
  2. RP2D:

    • This study will confirm Recommended Phase 2 DOse (RP2D) established from Phase I Clinical Trial in Cancer patients conducted in National University Hospital Singapore (MC/03/0616).
  3. Efficacy:

    • Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score. Change in BCVA letter gain of 0-4 will be considered as primary end point.
    • Change From Baseline in Central Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT).

[Assessment Time Frame: 4 weekly through 24 weeks]

Secondary endpoints:

  • Change in visual Acuity (Best Corrected Visual Acuity) of 5 or more letters.
  • Proportion of patients gaining ≥15, ≥10, ≥5, or ≥0 ETDRS letters in BCVA from baseline over time
  • Proportion of patients avoiding a loss of ≥15, ≥10, or ≥5 ETDRS letters in BCVA from baseline over time
  • Proportion of patients with absence of intraretinal fluid measured by OCT
  • Proportion of patients with absence of subretinal fluid measured by OCT [Assessment Time Frame: 4 weekly through 24 weeks]

Criteria for additional Therapy:

Once the treatment is stopped after the third dose, patients from all groups are eligible for additional therapy as open-label treatment if there is recurrence of disease activity, as defined by presence of any of the following criteria:

  1. Decrease of ≥5 letters in BCVA compared with average BCVA value over the previous two scheduled visits, owing to nAMD disease activity (as determined by the investigator).
  2. Increase of >50 µm in OCT-measured CST compared with the average CST value over the previous two scheduled visits.
  3. Recurrence of intra-retinal or sub-retinal fluid (if resolved previously)
  4. New macular hemorrhage

Patients in the placebo group will be given PRL3-zumab (6mg/kg) if they fulfil the criteria for additional therapy. Additional therapy will be continued in subsequent monitoring visit until the progression of disease, or end of the trial. If patients show clinical benefit from the treatment, additional doses could be given based on investigators' judgment.

Criteria for progression of disease:

  1. BCVA decreases by 15 letters or more from best recorded BCVA because of nAMD disease activity.
  2. an increase in OCT central retinal thickness 150 µm or more from lowest recorded measurement after 2 consecutive additional therapy occurring 1 month apart.
Read the detailed description

ASSESSMENTS:

Safety:

All adverse events (AEs) will be classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 or the latest version.

Treatment-emergent adverse events (TEAEs), Treatment-related TRAEs, serious TEAEs, TEAE of Grade 2 or greater, TEAEs leading to treatment discontinuation, and TEAEs leading to dose modification will be summarized respectively. Physical examination findings, Clinical laboratory data, vital signs will be summarized descriptively.

  1. . Ocular adverse event:

    Ocular adverse events will be identified at every drug administration visit followed by every 4 weeks (28 days) eye examination. Any ocular adverse events will be recorded and determined for possible or probable relation to study treatment. Post-injection complications including worsening visual acuity, change in vision, worsening macular oedema, vitreous hemorrhage, retinal pigment epithelium tears, retinal tear or detachments, inflammation and intra ocular pressure (IOP) alterations will be identified.

  2. . Non-ocular adverse events Patient safety will be evaluated based on physical examination, vital signs (blood pressure [systolic and diastolic], heart rate, respiratory rate, and temperature), clinical laboratory tests (hematology, liver and renal function). Patient safety will be assessed on an ongoing basis at every drug administration visit followed by 4 weeks after the last dose of treatment.

Efficacy:

Efficacy assessment will be performed 4 weeks from the first dose of treatment by

  1. . Visual Acuity (Best Corrected Visual Acuity) by ETDRS letter score
  2. . Central retinal thickness by OCT
  3. . Intraretinal fluid (IRF) and/ or subretinal fluid (SRF) by OCT

DURATION OF THE STUDY:

The duration of study treatment is 4 weeks and monitoring is 20 weeks. Total duration of study will be 24 weeks.

Treatment Period:

PRL3-zumab will be administered 3 times in 2-week interval within the first 4 weeks of study period. Treatment with be terminated in case of intolerable toxicity, patients meet the criteria for end-of-trial or withdrawal of consent.

Monitoring Period:

Monitoring will be done every 4 weeks, starting from 4 weeks after the 3rd dose of study medication. The total duration of Monitoring period will be 20 weeks (All 3 arms). The trial will be terminated in case of intolerable toxicity, patients meet criteria for end of trial or withdrawal of consent.

Sample Size Determination PRL3-zumab was administered intravenously with the dose of 6mg/kg in > 155 advanced cancer patients to date (14 Dec 2023) with no safety issue. No drug-related Serious Adverse Event was reported so far. This clinical trial is for extended indication of PRL3-zumab in nAMD disease.

Primary endpoint is adverse events, visual acuity, central retinal thickness and IRF and/or SRF. No. of evaluable patients for primary endpoint (minimum) in each cohort = 3 -6 Only patients who have received PRL3-ZUMAB are evaluable, patients who did not receive PRL3-ZUMAB may be replaced to achieve the total sample size.

Arm 1: PRL3-zumab 3mg/kg (n=6) Arm 2: PRL3-zumab 6mg/kg (n=6) Arm 3: Placebo (normal saline) (n=3)

Once the Recommended Phase 2 Dose (RP2D) is confirmed and endpoints have been assessed in this trial, this protocol will be amended to include a detailed design of a Phase II expanded study.

03

Conditions studied

  • Neovascular Age Related Macular Degeneration

Keywords

  • PRL3
  • PRL3-zumab
  • nAMD
  • Neovasclar Age Related Macular Degeneration
  • Wet AMD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with Neovascular Age-related Macular Degeneration (nAMD).
  2. Willing to provide written for the study.
  3. Patients undergoing intravitreal treatment having failed at least two Standard-of care treatments and be receiving ongoing intravitreal treatment at intervals of ≤ 8 weeks including Ranibizumab, Aflibercept, or Faricimab.
  4. Participants receiving intravitreal treatment at screening must complete a before enrolment. This wash-out period should be calculated based on five half-lives of the specific intravitreal treatment the participant is receiving.

    Below is the washing out period for some standard of care treatments.

    1. Ranibizumab (half-life: 9 days) requires a wash-out period of 45 days (7 weeks)
    2. Aflibercept (half-life: 11 days) requires a wash-out period of 55 days (8 weeks)
    3. Faricimab (half-life: 7.5 days) requires a wash-out period of 37.5 days (5 weeks)
    4. Bevacizumab (half-life: 6 days) requires a wash-out period of 30 days (4weeks)
  5. Subfoveal CNV or juxtafoveal/extrafoveal CNV with a subfoveal component related to the CNV activity identified by FFA or OCT (where CNV activity is defined as showing evidence of subretinal fluid, subretinal hyperreflective material, or leakage).
  6. BCVA ETDRS letter score of 78 to 24 (corresponding to a Snellen equivalent of approximately 20/32 to 20/320) in the study eye.
  7. Decrease in BCVA determined to be primarily the result of nAMD or DR/DME in the study eye.
  8. Presence of pigment epithelium detachment (PED), intraretinal fluid (IRF) and/or subretinal fluid (SRF) affecting the central subfield of the study eye on OCT.
  9. Adequate organ (liver and renal) and hematological functions as evidenced by the laboratory results obtained within 7 days of treatment which are within the normal range for the study population, or with abnormalities deemed not by the investigators.

Exclusion criteria

Exclusion Criteria:

  1. Scar, fibrosis, atrophy, or retinal pigment epithelial tears involving the central fovea in the study eye.
  2. Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with antiglaucoma medication) in the study eye.
  3. History of idiopathic or uveitis in the study eye.
  4. Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.
  5. Evidence of extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening/randomization.
  6. Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg).
  7. Patient is receiving systemic (only if higher than 10mg or equivalent of prednisolone daily) or other treatment for autoimmune disease or any other medical condition.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Group 1: PRL3-zumab 3mg/kg

    Biological: PRL3-ZUMAB

  • Experimental
    Group 2: PRL3-zumab 6mg/kg

    Biological: PRL3-ZUMAB

  • Placebo comparator
    Group 3: Placebo

    Other: Normal Saline (0.9% Sodium Chloride)

Interventions

  • BiologicalPRL3-ZUMAB

    The study will consist of 3 arms, PRL3-zumab 3mg/kg, 6mg/kg and placebo. PRL3-zumab will be administered intravenously in 2-week interval for 3 doses.

  • OtherNormal Saline (0.9% Sodium Chloride)

    Placebo group will be administered with normal saline, administered intravenously in 2-week interval for 3 doses.

06

What researchers measure

Primary outcomes

  1. Safety: Adverse Events according to CTCAE

    Frequency and severity of adverse events throughout the primary outcome assessment period will be assessed by the Investigator for severity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 or later.

    Time frame: 24 weeks

  2. Recommended Phase 2 Dose (PR2D)

    This study will confirm RP2D established from Phase I Clinical Trial conducted in National University Hospital (NUH) Singapore in Cancer patients (MC/03/0616).

    Time frame: 24 weeks

  3. Efficacy: Best Corrected Visual Acuity (BCVA) measured by ETDRS letter score

    Change From Baseline in Best Corrected Visual Acuity (BCVA) measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score will be monitored. Change in BCVA letter gains of 0-4 will be considered as primary outcome measure.

    Time frame: 24 weeks

  4. Efficacy: Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT)

    Change from Baseline in Central Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT) will be monitored

    Time frame: 24 weeks

Secondary outcomes

  1. Best Corrected Visual Acuity (BCVA) measured by ETDRS letter score

    Change in Best Corrected Visual Acuity (BCVA) of 5 or more letters measured by ETDRS letter score will be considered as secondary end point. Proportion of patients gaining ≥15, ≥10, ≥5, or ≥0 of ETDRS letters in BCVA from baseline over time will be monitored. Proportion of patients avoiding a loss of ≥15, ≥10, or ≥5 ETDRS letters in BCVA from baseline over time will be monitored

    Time frame: 24 weeks

  2. Intraretinal fluid measured by Optical Coherence Tomography (OCT)

    Proportion of patients with absence of intraretinal fluid measured by Optical Coherence Tomography (OCT) will be monitored

    Time frame: 24 weeks

  3. Subretinal fluid measured by Optical Coherence Tomography (OCT)

    Proportion of patients with absence of subretinal fluid measured by Optical Coherence Tomography (OCT) will be monitored

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • NUHS Department of Ophthalmology
    Singapore, Singapore
    Recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 23, 2026
StartActual
Oct 11, 2025
Primary completionEst.
Feb 7, 2027
CompletionEst.
Jul 7, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07547228
Lead sponsor
Intra-IMMUSG Pte Ltd
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Oct 11, 2025
Primary completion
Feb 7, 2027 (estimated)
Completion
Jul 7, 2027 (estimated)
Last update
Apr 29, 2026

Study contacts

Dr Koon Hwee Ang (David)
Contact
ang.koonhwee@intra-immusg.com
+65 65869661
Dr Min Thura
Contact
min.thura@intra-immusg.com
Prof Qi Zeng
study director · Intra-IMMUSG Pte Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PRL-3 Monoclonal Antibody PRL3-zumab

Start the discussion